Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Toxicology
Published in: Cardiovascular Toxicology 1/2018

01-02-2018

Exercise and Doxorubicin Treatment Modulate Cardiac Mitochondrial Quality Control Signaling

Authors: I. Marques-Aleixo, E. Santos-Alves, J. R. Torrella, P. J. Oliveira, J. Magalhães, A. Ascensão

Published in: Cardiovascular Toxicology | Issue 1/2018

Login to get access

Abstract

The cross-tolerance effect of exercise against heart mitochondrial-mediated quality control, remodeling and death-related mechanisms associated with sub-chronic Doxorubicin (DOX) treatment is yet unknown. We therefore analyzed the effects of two distinct chronic exercise models (endurance treadmill training—TM and voluntary free wheel activity—FW) performed during the course of the sub-chronic DOX treatment on mitochondrial susceptibility to permeability transition pore (mPTP), apoptotic and autophagic signaling and mitochondrial dynamics. Male Sprague–Dawley rats were divided into six groups (n = 6 per group): saline sedentary (SAL + SED), SAL + TM (12-weeks treadmill), SAL + FW (12-weeks voluntary free-wheel), DOX + SED [7-weeks sub-chronic DOX treatment (2 mg kg−1 week−1)], DOX + TM and DOX + FW. Apoptotic signaling and mPTP regulation were followed by measuring caspase 3, 8 and 9 activities, Bax, Bcl2, CypD, ANT, and cophilin expression. Mitochondrial dynamics (Mfn1, Mfn2, OPA1 and DRP1) and auto(mito)phagy (LC3, Beclin1, Pink1, Parkin and p62)-related proteins were semi-quantified. DOX treatment results in augmented mPTP susceptibility and apoptotic signaling (caspases 3, 8 and 9 and Bax/Bcl2 ratio). Moreover, DOX decreased the expression of fusion-related proteins (Mfn1, Mfn2, OPA1), increased DRP1 and the activation of auto(mito)phagy signaling. TM and FW prevented DOX-increased mPTP susceptibility and apoptotic signaling, alterations in mitochondrial dynamics and inhibits DOX-induced increases in auto(mito)phagy signaling. Collectively, our results suggest that both used chronic exercise models performed before and during the course of sub-chronic DOX treatment limit cardiac mitochondrial-driven apoptotic signaling and regulate alterations in mitochondrial dynamics and auto(mito)phagy in DOX-treated animals.
Literature
1.
Andreyev, A. Y., Fahy, B., & Fiskum, G. (1998). Cytochrome c release from brain mitochondria is independent of the mitochondrial permeability transition. FEBS Letters, 439, 373–376.CrossRefPubMed
2.
Ascensao, A., Ferreira, R., & Magalhaes, J. (2007). Exercise-induced cardioprotection–biochemical, morphological and functional evidence in whole tissue and isolated mitochondria. International Journal of Cardiology, 117, 16–30.CrossRefPubMed
3.
Ascensao, A., Ferreira, R., Oliveira, P. J., & Magalhaes, J. (2006). Effects of endurance training and acute Doxorubicin treatment on rat heart mitochondrial alterations induced by in vitro anoxia-reoxygenation. Cardiovascular Toxicology, 6, 159–172.CrossRefPubMed
4.
Ascensao, A., Lumini-Oliveira, J., Machado, N. G., Ferreira, R. M., Goncalves, I. O., Moreira, A. C., et al. (2011). Acute exercise protects against calcium-induced cardiac mitochondrial permeability transition pore opening in doxorubicin-treated rats. Clinical science (Lond), 120, 37–49.CrossRef
5.
Ascensao, A., Lumini-Oliveira, J., Oliveira, P. J., & Magalhaes, J. (2011). Mitochondria as a target for exercise-induced cardioprotection. Current Drug Targets, 12, 860–871.CrossRefPubMed
6.
Ascensao, A., Magalhaes, J., Soares, J., Ferreira, R., Neuparth, M., Marques, F., et al. (2005). Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. International Journal of Cardiology, 100, 451–460.CrossRefPubMed
7.
Ascensao, A., Magalhaes, J., Soares, J. M., Ferreira, R., Neuparth, M. J., Marques, F., et al. (2005). Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. American Journal of Physiology Heart and Circulatory Physiology, 289, H722–H731.CrossRefPubMed
8.
Ascensao, A., Oliveira, P. J., & Magalhaes, J. (2012). Exercise as a beneficial adjunct therapy during Doxorubicin treatment–role of mitochondria in cardioprotection. International Journal of Cardiology, 156, 4–10.CrossRefPubMed
9.
Baines, C. P., Kaiser, R. A., Sheiko, T., Craigen, W. J., & Molkentin, J. D. (2007). Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nature Cell Biology, 9, 550–555.CrossRefPubMedPubMedCentral
10.
11.
Bhattacharya, S. K., Thakar, J. H., Johnson, P. L., & Shanklin, D. R. (1991). Isolation of skeletal muscle mitochondria from hamsters using an ionic medium containing ethylenediaminetetraacetic acid and nagarse. Analytical Biochemistry, 192, 344–349.CrossRefPubMed
12.
Broekemeier, K. M., Dempsey, M. E., & Pfeiffer, D. R. (1989). Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. Journal of Biological Chemistry, 264, 7826–7830.PubMed
13.
14.
Carreira, R. S., Lee, Y., Ghochani, M., Gustafsson, A. B., & Gottlieb, R. A. (2010). Cyclophilin D is required for mitochondrial removal by autophagy in cardiac cells. Autophagy, 6, 462–472.CrossRefPubMedPubMedCentral
15.
Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014). Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Medicinal Research Reviews, 34, 106–135.CrossRefPubMed
16.
Chan, D. C. (2006). Mitochondria: Dynamic organelles in disease, aging, and development. Cell, 125, 1241–1252.CrossRefPubMed
17.
Chan, D. C. (2006). Mitochondrial fusion and fission in mammals. Annual Review of Cell and Developmental Biology, 22, 79–99.CrossRefPubMed
18.
Cheng, E. H., Sheiko, T. V., Fisher, J. K., Craigen, W. J., & Korsmeyer, S. J. (2003). VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science, 301, 513–517.CrossRefPubMed
19.
Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Research, 62, 4592–4598.PubMed
20.
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., et al. (2006). Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 441, 1162–1166.CrossRefPubMed
21.
Dimitrakis, P., Romay-Ogando, M. I., Timolati, F., Suter, T. M., & Zuppinger, C. (2012). Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. Cell and Tissue Research, 350, 361–372.CrossRefPubMed
22.
Dolinsky, V. W., Rogan, K. J., Sung, M. M., Zordoky, B. N., Haykowsky, M. J., Young, M. E., et al. (2013). Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. American journal of physiology. Endocrinology and metabolism, 305, E243–E253.CrossRefPubMedPubMedCentral
23.
Fontaine, E., Eriksson, O., Ichas, F., & Bernardi, P. (1998). Regulation of the permeability transition pore in skeletal muscle mitochondria. Modulation By electron flow through the respiratory chain complex I. Journal of Biological Chemistry, 273, 12662–12668.CrossRefPubMed
24.
Frank, S., Gaume, B., Bergmann-Leitner, E. S., Leitner, W. W., Robert, E. G., Catez, F., et al. (2001). The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Developmental Cell, 1, 515–525.CrossRefPubMed
25.
Gharanei, M., Hussain, A., Janneh, O., & Maddock, H. (2013). Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: A mitochondrial division/mitophagy inhibitor. PLoS ONE, 8, e77713.CrossRefPubMedPubMedCentral
26.
Gomes, L. C., & Scorrano, L. (2008). High levels of Fis1, a pro-fission mitochondrial protein, trigger autophagy. Biochimica et Biophysica Acta, 1777, 860–866.CrossRefPubMed
27.
Gornall, A. G., Bardawill, C. J., & David, M. M. (1949). Determination of serum proteins by means of the biuret reaction. Journal of Biological Chemistry, 177, 751–766.PubMed
28.
Gottlieb, R. A., & Carreira, R. S. (2010). Autophagy in health and disease. 5. Mitophagy as a way of life. American Journal of Physiology. Cell Physiology, 299, C203–C210.CrossRefPubMedPubMedCentral
29.
Green, P. S., & Leeuwenburgh, C. (2002). Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochimica et Biophysica Acta, 1588, 94–101.CrossRefPubMed
30.
Gustafsson, A. B., & Gottlieb, R. A. (2008). Heart mitochondria: Gates of life and death. Cardiovascular Research, 77, 334–343.CrossRefPubMed
31.
Hoshino, A., Mita, Y., Okawa, Y., Ariyoshi, M., Iwai-Kanai, E., Ueyama, T., et al. (2013). Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nature Communications, 4, 2308.CrossRefPubMed
32.
Jang, Y. M., Kendaiah, S., Drew, B., Phillips, T., Selman, C., Julian, D., et al. (2004). Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Letters, 577, 483–490.CrossRefPubMed
33.
Klamt, F., Zdanov, S., Levine, R. L., Pariser, A., Zhang, Y., Zhang, B., et al. (2009). Oxidant-induced apoptosis is mediated by oxidation of the actin-regulatory protein cofilin. Nature Cell Biology, 11, 1241–1246.CrossRefPubMedPubMedCentral
34.
35.
Kobayashi, S., Volden, P., Timm, D., Mao, K., Xu, X., & Liang, Q. (2010). Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. Journal of Biological Chemistry, 285, 793–804.CrossRefPubMed
36.
Krauskopf, A., Eriksson, O., Craigen, W. J., Forte, M. A., & Bernardi, P. (2006). Properties of the permeability transition in VDAC1(-/-) mitochondria. Biochimica et Biophysica Acta, 1757, 590–595.CrossRefPubMed
37.
38.
Kumar, D., Kirshenbaum, L. A., Li, T., Danelisen, I., & Singal, P. K. (2001). Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxidants & Redox Signaling, 3, 135–145.CrossRef
39.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680–685.CrossRefPubMed
40.
Lee, Y., Lee, H. Y., Hanna, R. A., & Gustafsson, A. B. (2011). Mitochondrial autophagy by Bnip3 involves Drp1-mediated mitochondrial fission and recruitment of Parkin in cardiac myocytes. American Journal of Physiology Heart and Circulatory Physiology, 301, H1924–H1931.CrossRefPubMedPubMedCentral
41.
Lee, Y. J., Jeong, S. Y., Karbowski, M., Smith, C. L., & Youle, R. J. (2004). Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Molecular Biology of the Cell, 15, 5001–5011.CrossRefPubMedPubMedCentral
42.
Liesa, M., Palacin, M., & Zorzano, A. (2009). Mitochondrial dynamics in mammalian health and disease. Physiological Reviews, 89, 799–845.CrossRefPubMed
43.
Lin, S. T., Chou, H. C., Chen, Y. W., & Chan, H. L. (2013). Redox-proteomic analysis of doxorubicin-induced altered thiol activity in cardiomyocytes. Molecular BioSystems, 9, 447–456.CrossRefPubMed
44.
Locke, M., Noble, E. G., & Atkinson, B. G. (1990). Exercising mammals synthesize stress proteins. American Journal of Physiology, 258, C723–C729.CrossRefPubMed
45.
Lu, L., Wu, W., Yan, J., Li, X., Yu, H., & Yu, X. (2009). Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. International Journal of Cardiology, 134, 82–90.CrossRefPubMed
46.
Lumini-Oliveira, J., Magalhaes, J., Pereira, C. V., Moreira, A. C., Oliveira, P. J., & Ascensao, A. (2011). Endurance training reverts heart mitochondrial dysfunction, permeability transition and apoptotic signaling in long-term severe hyperglycemia. Mitochondrion, 11, 54–63.CrossRefPubMed
47.
Marechal, X., Montaigne, D., Marciniak, C., Marchetti, P., Hassoun, S. M., Beauvillain, J. C., et al. (2011). Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics. Clinical science (London), 121, 405–413.CrossRef
48.
Marques-Aleixo, I., Santos-Alves, E., Mariani, D., Rizo-Roca, D., Padrao, A. I., Rocha-Rodrigues, S., et al. (2015). Physical exercise prior and during treatment reduces sub-chronic doxorubicin-induced mitochondrial toxicity and oxidative stress. Mitochondrion, 20, 22–33.CrossRefPubMed
49.
Marquez, R. T., & Xu, L. (2012). Bcl-2: Beclin 1 complex: Multiple, mechanisms regulating autophagy/apoptosis toggle switch. American Journal of Cancer Research, 2, 214–221.PubMedPubMedCentral
50.
Narendra, D., Kane, L. A., Hauser, D. N., Fearnley, I. M., & Youle, R. J. (2010). p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy, 6, 1090–1106.CrossRefPubMedPubMedCentral
51.
Nogueira, V., Devin, A., Walter, L., Rigoulet, M., Leverve, X., & Fontaine, E. (2005). Effects of decreasing mitochondrial volume on the regulation of the permeability transition pore. Journal of Bioenergetics and Biomembranes, 37, 25–33.CrossRefPubMed
52.
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., et al. (2004). Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicology and Applied Pharmacology, 200, 159–168.CrossRefPubMed
53.
Oliveira, P. J., & Wallace, K. B. (2006). Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats–relevance for mitochondrial dysfunction. Toxicology, 220, 160–168.CrossRefPubMed
54.
Ong, S. B., Subrayan, S., Lim, S. Y., Yellon, D. M., Davidson, S. M., & Hausenloy, D. J. (2010). Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation, 121, 2012–2022.CrossRefPubMed
55.
Papanicolaou, K. N., Khairallah, R. J., Ngoh, G. A., Chikando, A., Luptak, I., O’Shea, K. M., et al. (2011). Mitofusin-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes. Molecular and Cellular Biology, 31, 1309–1328.CrossRefPubMedPubMedCentral
56.
Papanicolaou, K. N., Ngoh, G. A., Dabkowski, E. R., O’Connell, K. A., Ribeiro, R. F., Jr., Stanley, W. C., et al. (2012). Cardiomyocyte deletion of mitofusin-1 leads to mitochondrial fragmentation and improves tolerance to ROS-induced mitochondrial dysfunction and cell death. American Journal of Physiology Heart and Circulatory Physiology, 302, H167–H179.CrossRefPubMed
57.
Papanicolaou, K. N., Phillippo, M. M., & Walsh, K. (2012). Mitofusins and the mitochondrial permeability transition: the potential downside of mitochondrial fusion. American Journal of Physiology Heart and Circulatory Physiology, 303, H243–H255.CrossRefPubMedPubMedCentral
58.
Parone, P. A., James, D. I., Da Cruz, S., Mattenberger, Y., Donze, O., Barja, F., et al. (2006). Inhibiting the mitochondrial fission machinery does not prevent Bax/Bak-dependent apoptosis. Molecular and Cellular Biology, 26, 7397–7408.CrossRefPubMedPubMedCentral
59.
Parra, V., Eisner, V., Chiong, M., Criollo, A., Moraga, F., Garcia, A., et al. (2008). Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovascular Research, 77, 387–397.CrossRefPubMed
60.
Pereira, G. C., Pereira, S. P., Pereira, C. V., Lumini, J. A., Magalhaes, J., Ascensao, A., et al. (2012). Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific. PLoS ONE, 7, e38867.CrossRefPubMedPubMedCentral
61.
Pereira, G. C., Silva, A. M., Diogo, C. V., Carvalho, F. S., Monteiro, P., & Oliveira, P. J. (2011). Drug-induced cardiac mitochondrial toxicity and protection: From doxorubicin to carvedilol. Current Pharmaceutical Design, 17, 2113–2129.CrossRefPubMed
62.
Pich, S., Bach, D., Briones, P., Liesa, M., Camps, M., Testar, X., et al. (2005). The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. Human Molecular Genetics, 14, 1405–1415.CrossRefPubMed
63.
Piquereau, J., Caffin, F., Novotova, M., Lemaire, C., Veksler, V., Garnier, A., et al. (2013). Mitochondrial dynamics in the adult cardiomyocytes: Which roles for a highly specialized cell? Frontiers in Physiology, 4, 102.CrossRefPubMedPubMedCentral
64.
Piquereau, J., Caffin, F., Novotova, M., Prola, A., Garnier, A., Mateo, P., et al. (2012). Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function, and cardiac adaptation to pressure overload. Cardiovascular Research, 94, 408–417.CrossRefPubMedPubMedCentral
65.
Santos, D. L., Moreno, A. J., Leino, R. L., Froberg, M. K., & Wallace, K. B. (2002). Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicology and Applied Pharmacology, 185, 218–227.CrossRefPubMed
66.
Scherz-Shouval, R., & Elazar, Z. (2011). Regulation of autophagy by ROS: Physiology and pathology. Trends in Biochemical Sciences, 36, 30–38.CrossRefPubMed
67.
Sciarretta, S., Hariharan, N., Monden, Y., Zablocki, D., & Sadoshima, J. (2011). Is autophagy in response to ischemia and reperfusion protective or detrimental for the heart? Pediatric Cardiology, 32, 275–281.CrossRefPubMed
68.
Sishi, B. J., Loos, B., van Rooyen, J., & Engelbrecht, A. M. (2013). Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochemical Pharmacology, 85, 124–134.CrossRefPubMed
69.
Smuder, A. J., Kavazis, A. N., Min, K., & Powers, S. K. (2011). Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle. Journal of Applied Physiology, 111, 1190–1198.CrossRefPubMed
70.
Smuder, A. J., Kavazis, A. N., Min, K., & Powers, S. K. (2013). Doxorubicin-induced markers of myocardial autophagic signaling in sedentary and exercise trained animals. Journal of Applied Physiology, 115, 176–185.CrossRefPubMed
71.
Sun, M., Shen, W., Zhong, M., Wu, P., Chen, H., & Lu, A. (2013). Nandrolone attenuates aortic adaptation to exercise in rats. Cardiovascular Research, 97, 686–695.CrossRefPubMed
72.
Szigeti, A., Hocsak, E., Rapolti, E., Racz, B., Boronkai, A., Pozsgai, E., et al. (2010). Facilitation of mitochondrial outer and inner membrane permeabilization and cell death in oxidative stress by a novel Bcl-2 homology 3 domain protein. Journal of Biological Chemistry, 285, 2140–2151.CrossRefPubMed
73.
Tanaka, A., Cleland, M. M., Xu, S., Narendra, D. P., Suen, D. F., Karbowski, M., et al. (2010). Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. Journal of Cell Biology, 191, 1367–1380.CrossRefPubMedPubMedCentral
74.
Twig, G., Elorza, A., Molina, A. J., Mohamed, H., Wikstrom, J. D., Walzer, G., et al. (2008). Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO Journal, 27, 433–446.CrossRefPubMedPubMedCentral
75.
Wallace, K. B. (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacology and Toxicology, 93, 105–115.CrossRefPubMed
76.
Wallace, K. B. (2007). Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovascular Toxicology, 7, 101–107.CrossRefPubMed
77.
Wang, G. W., Klein, J. B., & Kang, Y. J. (2001). Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. Journal of Pharmacology and Experimental Therapeutics, 298, 461–468.PubMed
78.
Wang, X. L., Wang, X., Xiong, L. L., Zhu, Y., Chen, H. L., Chen, J. X., et al. (2013). Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. Journal of Cardiovascular Pharmacology, 62, 512–523.CrossRefPubMed
79.
Wasilewski, M., & Scorrano, L. (2009). The changing shape of mitochondrial apoptosis. Trends in Endocrinology and Metabolism, 20, 287–294.CrossRefPubMed
80.
Whelan, R. S., Konstantinidis, K., Wei, A. C., Chen, Y., Reyna, D. E., Jha, S., et al. (2012). Bax regulates primary necrosis through mitochondrial dynamics. Proceedings of the National Academy of Sciences USA, 109, 6566–6571.CrossRef
81.
Xu, X., Chen, K., Kobayashi, S., Timm, D., & Liang, Q. (2012). Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. Journal of Pharmacology and Experimental Therapeutics, 341, 183–195.CrossRefPubMedPubMedCentral
82.
83.
Zhang, Y. W., Shi, J., Li, Y. J., & Wei, L. (2009). Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Archivum immunologiae et therapiae experimentalis, 57, 435–445.CrossRefPubMedPubMedCentral
84.
Zheng, Q., & Wang, X. (2010). Autophagy and the ubiquitin-proteasome system in cardiac dysfunction. Panminerva Medica, 52, 9–25.PubMedPubMedCentral
85.
Zhou, S., Palmeira, C. M., & Wallace, K. B. (2001). Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicology Letters, 121, 151–157.CrossRefPubMed
86.
Zhou, S., Starkov, A., Froberg, M. K., Leino, R. L., & Wallace, K. B. (2001). Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Research, 61, 771–777.PubMed
Metadata
Title
Exercise and Doxorubicin Treatment Modulate Cardiac Mitochondrial Quality Control Signaling
Authors
I. Marques-Aleixo
E. Santos-Alves
J. R. Torrella
P. J. Oliveira
J. Magalhães
A. Ascensão
Publication date
01-02-2018
Publisher
Springer US
Published in
Cardiovascular Toxicology / Issue 1/2018
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-017-9412-4

Other articles of this Issue 1/2018

Cardiovascular Toxicology 1/2018 Go to the issue

OriginalPaper

Impact of Diclofenac Sodium on Tilmicosin-Induced Acute Cardiotoxicity in Rats (Tilmicosin and Diclofenac Cardiotoxicity)

OriginalPaper

Protective Role of N-Acetylcysteine on Isoprenaline-Induced Myocardial Injury: Histological, Immunohistochemical and Morphometric Study

OriginalPaper

Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents

OriginalPaper

Sodium Butyrate Controls Cardiac Hypertrophy in Experimental Models of Rats

OriginalPaper

Effects of Remifentanil Pretreatment on Bupivacaine Cardiotoxicity in Rats

OriginalPaper

Modulatory Effect of Aerobic Exercise Training on Doxorubicin-Induced Cardiotoxicity in Rats with Different Ages

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits